Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14163791 | 0.80 | FFAR3 (0.33) | FFAR3 | |
| SCHEMBL4910463 | 0.75 | HMGCR (0.36) | FFAR3HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL11416604 | 0.66 | ACLY (0.34) | — | |
| Propionic Acid SCHEMBL28846408 | 0.63 | — | — | |
| Propionic Acid SCHEMBL10493407 | 0.63 | FFAR3 (0.67) | FFAR3 | |
| SCHEMBL6045407 | 0.62 | — | — | |
| Propionic Acid SCHEMBL11421514 | 0.61 | — | — | |
| SCHEMBL9640216 | 0.61 | — | — | |
| SCHEMBL4558912 | 0.61 | TDP1 (0.37) | FFAR3 | |
| SCHEMBL2177849 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687301-B1 | THIAEPOTHILONE FOR TREATING CANCEROUS DISEASES | LEIBNIZ INST FUER PFLANZENBIOC (DE) | 2009-05-13 | — | — | EP | claimed |
| EP-1687301-B1 | THIAEPOTHILONE FOR TREATING CANCEROUS DISEASES | LEIBNIZ INST FUER PFLANZENBIOC (DE) | 2009-05-13 | — | — | EP | disclosed |
| US-7381743-B2 | Macrocycles for the treatment of cancer | LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) | 2008-06-03 | — | — | US | disclosed |
| US-7381743-B2 | Macrocycles for the treatment of cancer | LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) | 2008-06-03 | — | — | US | disclosed |
| US-20070105905-A1 | Novel macrocycles for the treatment of cancer | LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105905-A1 | Novel macrocycles for the treatment of cancer | LEIBNIZ-INSTITUT FUER PFLANZENBIOCHEMIE (IPB) (DE) | 2007-05-10 | — | — | US | disclosed |
| EP-1687301-A1 | THIAEPOTHILONE FOR TREATING CANCEROUS DISEASES | LEIBNIZ-INSTITUT FÜR PFLANZENBIOCHEMIE (IPB) (DE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051947-A1 | THIAEPOTHILONE FOR TREATING CANCEROUS DISEASES | LEIBNIZ-INSTITUT FÜR PFLANZENBIOCHEMIE (IPB) (DE) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105905-A1 | Novel macrocycles for the treatment of cancer | HCCS, FOLR1, AURKAIP1 | FFAR3 3736/4885HMGCR 1522/4885CHRM1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.